Skip to main content
Premium Trial:

Request an Annual Quote

CalbaTech to Acquire KSE Scientific; Purchase Amount Undisclosed

NEW YORK, Dec. 1 (GenomeWeb News) - CalbaTech today said it plans to acquire laboratory supplies distributor KSE Scientific for an undisclosed sum.

 

Irvine, Calif.-based CalbaTech said the acquisition would strengthen its position in the life sciences market by adding a large-scale distribution operation to sell products from its research reagents division. That division includes its MoleculA unit and the recently acquired K-D Medical.

 

CalbaTech also has a molecular applications division, which is developing pathogen microarrays, diagnostics, and electronic-based DNA detection systems, and a division developing cell-based therapies.

 

Research Triangle Park, NC-based KSE, which is privately held, had revenues in excess of $5.1 million in 2003 and is expected to bring in revenue of more than $6.7 million in 2004, CalbaTech said today. Among the firm's customers are Labcorp, the National Cancer Institute, and Mayo Clinic.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.